Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of Evorpacept (ALX148) in Combination With Azacitidine in Patients With Higher Risk Myelodysplastic Syndrome (MDS) (ASPEN-02)

Next Previous
Search
Trial Profile

A Phase 1/2 Study of Evorpacept (ALX148) in Combination With Azacitidine in Patients With Higher Risk Myelodysplastic Syndrome (MDS) (ASPEN-02)

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 16 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Evorpacept (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ASPEN-02
  • Sponsors ALX Oncology

Most Recent Events

  • 05 Mar 2024 According to a ALX Oncology media release ,company announced that this trial have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting, which will be held in San Diego from April 5-10, 2024.
  • 03 Sep 2023 This trial has been completed in Belgium according to European Clinical Trials Database record.
  • 11 Aug 2023 According to a ALX Oncology media release ,Patients currently on trial may continue in the study and the Company plans to present the full data set from the forty-five subjects at an upcoming scientific conference.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top